Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 2/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.79 |
| ▸ | MAPT | P10636 | 7/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.79 |
| ▸ | BLM | P54132 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | LMNA | P02545 | 6/20 | 0.79 |
| ▸ | TSHR | P16473 | 5/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.79 |
| ▸ | HPGD | P15428 | 5/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 5/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.79 |
| ▸ | RGS12 | O14924 | 4/20 | 0.79 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351372 | 1.00 | CISD1 (1.00) | CISD1IGF1RMEN1KMT2AMAPT | |
| Tyrphostin A9 SCHEMBL120440 | 0.89 | MEN1 (1.00) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL10144266 | 0.86 | IGF1R (0.76) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL11759421 | 0.81 | MEN1 (0.79) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL11760765 | 0.81 | MEN1 (0.79) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL25800807 | 0.79 | MEN1 (0.74) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL10186365 | 0.79 | EGFR (0.70) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL4328828 | 0.75 | EGFR (1.00) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL5376916 | 0.75 | IGF1R (0.59) | CISD1IGF1RMEN1KMT2AMAPT | |
| SCHEMBL22817483 | 0.74 | MAPT (0.68) | CISD1IGF1RMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4064266-A | Compositions for killing internal parasites containing 3-tert-alkyl-4-hydroxy-5-halo-benzylidene-malonitriles | ICI AUSTRALIA LIMITED (AU) | 1977-12-20 | — | — | US | claimed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541379-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-11-19 | — | — | EP | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4640241-A2 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | Advanced Accelerator Applications S.A. (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-09-25 | — | — | US | disclosed |
| US-20160144028-A1 | COMBINATION THERAPY USING DUAL INHIBITOR OF C-MET AND EGFR AND IGF-1R INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-05-26 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20150374767-A1 | Treatment of Cancer | VIRTTU BIOLOGICS LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| EP-2914622-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014128487-A1 | TREATMENT OF CANCER | VIRTTU BIOLOGICS LIMITED (GB) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014071419-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-4064266-A | Compositions for killing internal parasites containing 3-tert-alkyl-4-hydroxy-5-halo-benzylidene-malonitriles | ICI AUSTRALIA LIMITED (AU) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374767-A1 | Treatment of Cancer | EGFR, ERBB2, MET | CISD1 4670/4885IGF1R 27/4885MEN1 3346/4885 |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | CISD1 4014/4885IGF1R 1613/4885MEN1 4026/4885 |
| US-20160144028-A1 | COMBINATION THERAPY USING DUAL INHIBITOR OF C-MET AND EGFR AND IGF-1R INHIBITOR | MET, IGF1R, EGFR | CISD1 1347/4885IGF1R 2/4885MEN1 243/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | CISD1 1794/4885IGF1R 3025/4885MEN1 3033/4885 |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | CISD1 2926/4885IGF1R 1645/4885MEN1 91/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | CISD1 1794/4885IGF1R 3025/4885MEN1 3033/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | CISD1 2240/4885IGF1R 3166/4885MEN1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.